2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy
Why the study?
New evidence emerged to update recommendations from the 2020 guideline for guiding clinicians in the management of patients with hypertrophic cardiomyopathy.
Population
Patients with hypertrophic cardiomyopathy
Design
Clinical practice guideline based on comprehensive literature search
Authors
Discussion
Loading...
Member takes
Implication
Integrates myosin inhibitors before SRT for obstructive HCM; extends 2020 guideline with updated exercise, SCD risk, and shared decision-making recommendations.**[[1]](https://www.jacc.org/doi/10.1016/j.jacc.2024.04.002)[[2]](https://professional.heart.
Structured PICO
P
Population
Patients with hypertrophic cardiomyopathy
I
Intervention
Management of hypertrophic cardiomyopathy
This document provides updated 2024 clinical practice guidelines for the management of hypertrophic cardiomyopathy.
Cite This Study
Ommen et al. (2024) studied this question.